Aerosolized Intratracheal Inoculation of Recombinant Protective Antigen (rPA) Vaccine Provides Protection Against Inhalational Anthrax in B10.D2-Hc0 Mice

Anthrax caused by Bacillus anthracis is a fatal zoonotic disease with a high lethality and poor prognosis. Inhalational anthrax is the most severe of the three forms of anthrax. The currently licensed commercial human anthrax vaccines require a complex immunization procedure for efficacy and have side effects that limit its use in emergent situations. Thus, development of a better anthrax vaccine is necessary. In this study, we evaluate the potency and efficacy of aerosolized intratracheal (i.t.) inoculation with recombinant protective antigen (rPA) subunit vaccines against aerosolized B. anthracis Pasteur II spores (an attenuated strain) challenge in a B10.D2-Hc0 mouse (deficient in complement component C5) model. Immunization of rPA in liquid, powder or powder reconstituted formulations via i.t. route conferred 100% protection against a 20× LD50 aerosolized Pasteur II spore challenge in mice, compared with only 50% of subcutaneous (s.c.) injection with liquid rPA. Consistently, i.t. inoculation of rPA vaccines induced a higher lethal toxin (LeTx) neutralizing antibody titer, a stronger lung mucosal immune response and a greater cellular immune response than s.c. injection. Our results demonstrate that immunization with rPA dry powder vaccine via i.t. route may provide a stable and effective strategy to improve currently available anthrax vaccines and B10.D2-Hc0 mice challenged with B. anthracis attenuated strains might be an alternative model for anthrax vaccine candidate screening.

[1]  Yun-zhou Yu,et al.  Intratracheal inoculation of AHc vaccine induces protection against aerosolized botulinum neurotoxin A challenge in mice , 2021, NPJ vaccines.

[2]  B. Narasimhan,et al.  Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against Bacillus anthracis. , 2021, Vaccine.

[3]  Xudong Liang,et al.  Identification of the pXO1 plasmid in attenuated Bacillus anthracis vaccine strains , 2016, Virulence.

[4]  H. Staats,et al.  Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  N. Petrovsky,et al.  Advax-Adjuvanted Recombinant Protective Antigen Provides Protection against Inhalational Anthrax That Is Further Enhanced by Addition of Murabutide Adjuvant , 2014, Clinical and Vaccine Immunology.

[6]  Q. Sattentau,et al.  Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission , 2013, AIDS.

[7]  Amber D. Miller,et al.  IgA is Important for Clearance and Critical for Protection from Rotavirus Infection , 2012, Mucosal Immunology.

[8]  Anthony J Hickey,et al.  Stable dry powder formulation for nasal delivery of anthrax vaccine. , 2012, Journal of pharmaceutical sciences.

[9]  G. Matyas,et al.  Anthrax Vaccine Antigen-Adjuvant Formulations Completely Protect New Zealand White Rabbits against Challenge with Bacillus anthracis Ames Strain Spores , 2011, Clinical and Vaccine Immunology.

[10]  Sandra Jesus,et al.  Recent Developments in the Nasal Immunization against Anthrax , 2011 .

[11]  Qin Li,et al.  Highly effective generic adjuvant systems for orphan or poverty-related vaccines. , 2011, Vaccine.

[12]  N. Twenhafel.  Pathology of Inhalational Anthrax Animal Models , 2010, Veterinary pathology.

[13]  A. O’Brien,et al.  Anthrax vaccination strategies. , 2009, Molecular aspects of medicine.

[14]  A. Friedlander,et al.  Advances in the development of next-generation anthrax vaccines. , 2009, Vaccine.

[15]  H. Junginger,et al.  Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[16]  B. Bloom,et al.  Immunization by a bacterial aerosol , 2008, Proceedings of the National Academy of Sciences.

[17]  U. Le,et al.  Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens. , 2008, FEMS immunology and medical microbiology.

[18]  H. Staats,et al.  Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination , 2007, AAPS PharmSciTech.

[19]  Vincent J. Sullivan,et al.  Formulation of a dry powder influenza vaccine for nasal delivery , 2006, AAPS PharmSciTech.

[20]  J. Grabenstein.  Vaccines: countering anthrax: vaccines and immunoglobulins. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Gerrit Borchard,et al.  Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  S. Wasserman,et al.  Safety, Reactogenicity, and Immunogenicity of a Recombinant Protective Antigen Anthrax Vaccine Given to Healthy Adults , 2007, Human vaccines.

[23]  James R. Baker,et al.  Mucosal Immunization with a Novel Nanoemulsion-Based Recombinant Anthrax Protective Antigen Vaccine Protects against Bacillus anthracis Spore Challenge , 2007, Infection and Immunity.

[24]  J. Grabenstein.  Countering Anthrax : Vaccines and Immunoglobulins , 2007 .

[25]  Vincent J. Sullivan,et al.  Microneedle-Based Intradermal Delivery of the Anthrax Recombinant Protective Antigen Vaccine , 2006, Infection and Immunity.

[26]  W. Keitel,et al.  Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. , 2006, Vaccine.

[27]  Brian R. Sloat,et al.  Nasal Immunization with Anthrax Protective Antigen Protein Adjuvanted with Polyriboinosinic–Polyribocytidylic Acid Induced Strong Mucosal and Systemic Immunities , 2006, Pharmaceutical Research.

[28]  T. Hoover,et al.  Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits. , 2006, Vaccine.

[29]  S. Leppla,et al.  Correlation between Lethal Toxin-Neutralizing Antibody Titers and Protection from Intranasal Challenge with Bacillus anthracis Ames Strain Spores in Mice after Transcutaneous Immunization with Recombinant Anthrax Protective Antigen , 2006, Infection and Immunity.

[30]  T. Merkel,et al.  Complement Depletion Renders C57BL/6 Mice Sensitive to the Bacillus anthracis Sterne Strain , 2005, Infection and Immunity.

[31]  Vincent J. Sullivan,et al.  Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. , 2005, The Journal of infectious diseases.

[32]  L. Goodman.  Taking the sting out of the anthrax vaccine. , 2004, The Journal of clinical investigation.

[33]  B. Ivins,et al.  Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. , 2004, Vaccine.

[34]  J. Shiloach,et al.  Development of an improved vaccine for anthrax. , 2002, The Journal of clinical investigation.

[35]  A. Friedlander,et al.  Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid. , 2002, Vaccine.

[36]  A. Friedlander,et al.  Anthrax vaccine: short-term safety experience in humans. , 2001, Vaccine.

[37]  S. Davis,et al.  Chitosan as a novel nasal delivery system for vaccines. , 2001, Advanced drug delivery reviews.

[38]  B. Ivins,et al.  In vitro correlate of immunity in a rabbit model of inhalational anthrax. , 2001, Vaccine.

[39]  B. Ivins,et al.  Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. , 2001, Vaccine.

[40]  C. Witham,et al.  A powder formulation of measles vaccine for aerosol delivery. , 2001, Vaccine.

[41]  A. Donaldson,et al.  Protection of cattle against rinderpest by intranasal immunisation with a dry powder tissue culture vaccine. , 2000, Vaccine.

[42]  L. Baillie,et al.  Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. , 1998, Vaccine.

[43]  B. Ivins,et al.  Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. , 1996, Vaccine.

[44]  S. Leppla,et al.  Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin , 1990, Infection and immunity.

[45]  S. Welkos,et al.  Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. , 1988, Microbial pathogenesis.

[46]  S. Little,et al.  Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig , 1986, Infection and immunity.

[47]  J. Melling,et al.  Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity , 1986, Infection and immunity.

[48]  S. Welkos,et al.  Differences in susceptibility of inbred mice to Bacillus anthracis , 1986, Infection and immunity.

[49]  J. Ezzell,et al.  Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin , 1984, Infection and immunity.

[50]  B. Ivins,et al.  Evidence for plasmid-mediated toxin production in Bacillus anthracis , 1983, Infection and immunity.

[51]  S. Plotkin,et al.  Field Evaluation of a Human Anthrax Vaccine. , 1962, American journal of public health and the nation's health.

[52]  J. Barnes.  The Development of Anthrax following the Administration of Spores by Inhalation , 1947 .